Peripheral Arterial Disease
Conditions
Brief summary
The BARISTA study tests the safety and efficacy of the Restorer stent from the company iVascular. This stent is a medical device that is already approved for use in Europe, to treat stenotic (narrowed) iliac arteries. 200 Belgian patients from 13 different hospitals will be included in this study. Patients will be medically monitored for 2 years from the day of the study procedure. The treatment of the stenotic iliac arteries will be according to the standard of care, using the Restorer stent. This endovascular treatment consists of introducing the necessary materials in the blood vessels by a puncture in the groin under general or local anaesthesia, after which a thin plastic tube will be inserted into the femoral artery through the puncture site, until the stenotic iliac artery is reached. Medical imaging is done by angiography. The stenotic/occluded section of the artery will first be dilated by inserting and inflating a balloon. Next, the Restorer stent will be placed and, if necessary, another balloon may be inserted and inflated to allow the stent to fit nicely to the vessel wall and optimise the result. As per standard of care, follow-up will be done in the hospital after 1, 6, 12, and 24 months. During these visits, an ultrasound scan of the treated artery will be taken to evaluate the patency of the blood vessel. Also, two short questionnaires will be completed asking about the quality of life and walking difficulties. The use of medication will be recorded. If adverse events are experienced, they will be reported.
Detailed description
Prospective, single-arm, multicentre, physician-initiated clinical study to assess the long-term (up to 24 months) safety and efficacy of the RESTORER peripheral stent system (iVascular) for the treatment of iliac lesions in 200 subjects, in a controlled clinical setting post CE-certification when used according to the IFU with focus on the treatment of complex TASC A, B, C and D Aorto-iliac lesions. The primary endpoint of the study is freedom of any TLR, major amputation or restenosis (defined as significant stenosis on duplex ultrasound (\>50%, systolic velocity ratio greater than 2.4) within 12 months. Secondary endpoints are: technical success during procedure, and during the follow-up period: primary patency, stent graft occlusion rate, ABI, freedom from target lesion revascularization, clinical success (improvement of Rutherford classification), change in walking impairment questionnaire, change in quality of life questionnaire, freedom from above-the-ankle target limb amputation, and mortality. A subanalysis will be done to compare the results using the TASC classification, lesion location (AIE, AIC, bilateral, kissing configuration), gender, diabetes mellitus and Rutherford in terms of patency, frequency of TLR and clinical outcome at 12 and 24 months.
Interventions
DEVICERestorer Iliac Stent System
Not applicable (only one intervention)
Sponsors
ID3 Medical
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All patients will receive the Restorer stent of iVascular according to the IFU. Prospective, single-arm, multicentre, physician-initiated clinical study to assess the safety and efficacy of the study device during a two year FU period.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males or non-pregnant females ≥ 18 years of age at the time of consent. Females of childbearing potentials have a negative pregnancy test \<7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation. Female participants will be exempted from this requirement in case they are sterile, infertile or have been post-menopausal for at least 12 months. 2\. Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study. 3\. Patient presenting with a stenotic or occlusive lesion at the Aorto-iliac arteries suitable for stenting with the Restorer stent (iVascular) (on indication for primary stenting, based on the discretion of the investigator). This lesion is corresponding to the CE-mark indications/contra-indications and according to the current medical guidelines for minimally invasive peripheral interventions. 4\. Estimated life expectancy ≥ 2 years. 5. Patient presenting a score from 2 to 4 following Rutherford classification. 6. Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study. 7\. The target lesion has angiographic evidence of stenosis or restenosis \>50% or occlusion which can be passed with standard guidewire manipulation. 8\. There is angiographic evidence of a patent Common and Deep Femoral Artery. \-
Exclusion criteria
1. Patients with a history of coagulation disorders, 2. Presence of an aneurysm immediately adjacent of the site of stent implantation, 3. Extension of more than 1cm in distal aorta, 4. Extension into CFA, 5. Fresh thrombus formation, 6. Acute limb ischemia, defined as symptom onset during less than 14 days prior to the index procedure, 7. Any systemic infection or immunocompromised state. Patients with an ascending infection/deep foot infection or abscess/white blood count (WBC)≥12.000/or febrile state or CRP\>5mg/L, 8. Existing stent implant in the target vessel, 9. Use of alternative therapies: atherectomy, cutting/scoring balloons, laser, … 10. Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood disorder, or a platelet count less than 80.000/µL or greater than 500.000/µL, 11. Any subject in which antiplatelet, anticoagulant or thrombolytic therapy is contraindicated, 12. Known hypersensitivity or contraindication to the stent material (CoCr L605), 13. Has other comorbidities that, in the opinion of the investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up, 14. Known hypersensitivity or allergy to contrast agents that cannot be medically managed, 15. Inadequate inflow lesion treatment (\>30% residual stenosis), 16. Subject has IFU listed contraindication(s). \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Freedom from restenosis | 12 months | No significant stenosis on duplex ultrasound (\>50% stenosis or systolic velocity ratio greater than 2.4) |
| Freedom from TLR | 12 months | Freedom from any Target Lesion Revascularization (TLR) at 12 months |
| Freedom from major amputation | 12 months | Freedom from amputation above the ankle |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ABI | 6, 12, and 24 months | comparison of Ankle Brachial Index at follow-up compared to baseline ABI |
| Freedom from Target Lesion Revascularization | 12 and 24 months | freedom from repeated intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge |
| Technical success | 1 month | final residual angiographic stenosis \<30% |
| Change in Quality of Life | baseline, 6, 12, and 24 months | Change in Quality-of-Life Questionnaire (EQ5D) at follow-up, compared to baseline |
| Limb salvage | 6, 12, 24 months | Freedom from any above-the-ankle target limb amputation |
| Clinical improvement of at least one Rutherford classification | baseline, 6, 12, 24 months | Clinical improvement of at least one Rutherford classification (RCC) compared to pre-procedure RCC |
| Primary patency rate | 6, 12, and 24 months | lack of restenosis and no need for reintervention of the target lesion |
| Stent graft occlusion rate | 1, 6, 12, and 24 months | Presence or absence of occlusion |
Countries
Belgium
Outcome results
None listed